Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis
AUTOR(ES)
Tanaka, Masao
FONTE
American Society for Clinical Investigation
RESUMO
In an attempt to isolate disease-associated autoantigens in rheumatoid arthritis (RA), we cloned a new autoantigen named gp130-RAPS, which is a novel soluble form of the IL-6 signal–transducing molecule gp130. gp130-RAPS is a 50-kDa protein translated from alternatively spliced mRNA and has a truncated form of gp130 with a unique sequence, Asn-Ile-Ala-Ser-Phe (NIASF), in its COOH-terminus. We observed serum antibodies to this NIASF sequence frequently in patients with RA, but not in those with other systemic rheumatic diseases or in healthy subjects. In RA, detection of those antibodies was significantly associated with disease activity indices such as serum C–reactive protein (CRP) levels, erythrocyte sedimentation rate, blood platelet counts, and serum IL-6 concentration. In vitro experiments revealed that gp130-RAPS inhibited IL-6 activity, and this inhibition was neutralized by antibodies to the COOH-terminus of gp130-RAPS derived from patients with RA. Thus, autoantibody to gp130-RAPS may play an important role in the progression of RA by promoting IL-6 activity. Inspection of autoantibodies to gp130-RAPS may become a practical clinical test for RA. gp130-RAPS and its autoantibody provide a new clue to the complicated pathogenesis of RA.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=314355Documentos Relacionados
- Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
- Signaling through a Novel Domain of gp130 Mediates Cell Proliferation and Activation of Hck and Erk Kinases
- Differential regulation of interleukin-6 receptor and gp130 gene expression in rat hepatocytes.
- Conjugal prevalence of rheumatoid arthritis, rheumatoid factor, and other autoantibodies in rheumatoid arthritis.
- NEW EMBO MEMBERS’ REVIEW: Receptor recognition by gp130 cytokines